Nycomed and Affitech extend research deal:
This article was originally published in Clinica
Executive Summary
Nycomed Amersham Imaging and Norwegian company Affitech have signed a research agreement for the discovery of fully human antibodies for diagnostic use. This extends a 1999 collaboration deal. Oslo-based Affitech will combine its proprietary antibody library technology and its automated affinity maturation process to generate human antibodies against targets provided by Nycomed. Affitech has rights to milestone and royalty payments from any products incorporating its technology.